Opioid Efficacy: A Twin-Study - Full Text View

Opioid Efficacy: A Twin-Study

This study is not yet open for participant recruitment.
Verified by Stanford University, May 2008

Sponsors and Collaborators:	Stanford University SRI
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00672438

Purpose

Proposed twin study will test to what degree inter-individual differences in pain sensitivity and amount of pain relief in response to opioid therapy are inherited or alternatively, are due to environmental factors. This knowledge is important to guide future studies trying to explain such inter-individual differences. For example, finding that differences are largely due to environmental factors would discourage genomic studies and emphasize epidemiological studies.

Condition	Intervention
Pain	Drug: Alfentanil

Drug Information available for:

Alfentanil Alfentanil hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Other, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study

Official Title:	Opioid Efficacy: A Twin-Study

Further study details as provided by Stanford University:

Primary Outcome Measures:

To what degree are inter-individual differences in pain sensitivity and pain relief in response to opioid therapy inherited.

Secondary Outcome Measures:

To what degree are inter-individual differences in other effects of opioid medications inherited.

Estimated Enrollment:	250
Study Start Date:	May 2008

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Monozygotic or dizygotic twins
Ages 18-70

Exclusion Criteria:

Clinically relevant systemic diseases such as psychiatric, neurological, and dermatological conditions interfering with the collection and interpretation of study data
History of addiction
Allergy to study medication
Chronic intake of medication potentially interfering with pain processing (except oral contraceptives)
Intake of over-the-counter analgesics within the two days prior to study
Reynaud's disease
pregnancy
Participation in other study within last 30 days
Personnel with direct access to addicting drugs

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00672438

Locations


United States, California
	Stanford University School of Medicine
	Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

SRI

Investigators


Principal Investigator:	David J. Clark	Stanford University

Sub-Investigator:	David R. Drover	Stanford University

Principal Investigator:	Martin S Angst	Stanford University

More Information

Study ID Numbers:	SU-04212008-1119, IRB # 13018
First Received:	May 2, 2008
Last Updated:	May 5, 2008
ClinicalTrials.gov Identifier:	NCT00672438
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Alfentanil

Pain

Additional relevant MeSH terms:

Anesthetics, Intravenous

Physiological Effects of Drugs

Central Nervous System Depressants

Anesthetics

Narcotics

Pharmacologic Actions

Sensory System Agents

Anesthetics, General

Therapeutic Uses

Analgesics

Peripheral Nervous System Agents

Central Nervous System Agents

Analgesics, Opioid

ClinicalTrials.gov processed this record on October 24, 2008